study_id,year,design,effect_type,effect_point,ci_low,ci_high,n_treat,n_ctrl,risk_of_bias,doi,journal_id,outcome,population,adverse_events,duration_weeks
INFL-INF07-01,2020,randomized controlled trial,SMD,-0.2964,-0.4858,-0.107,82,95,some concerns,10.1234/infl-inf07-01,inflammation-journal-01,systemic_inflammation,Adults with systemic inflammation concerns,None reported,13
INFL-INF07-02,2011,randomized controlled trial,SMD,-0.291,-0.4628,-0.1192,95,80,mixed,10.1234/infl-inf07-02,inflammation-journal-02,systemic_inflammation,Adults with systemic inflammation concerns,None reported,12
INFL-INF07-03,2016,randomized controlled trial,SMD,-0.2856,-0.4398,-0.1314,78,94,mixed,10.1234/infl-inf07-03,inflammation-journal-03,systemic_inflammation,Adults with systemic inflammation concerns,Transient headache,10
